Key result
Evening administration of candesartan resulted in a more pronounced reduction in albumin excretion rate compared to morning administration, despite similar achieved blood pressure levels.
Why the study?
Does evening administration of candesartan reduce albumin excretion rate compared to morning administration in hypertensive patients?
Does evening administration of candesartan reduce albumin excretion rate compared to morning administration in hypertensive patients?
Answers are grounded in this paper and cite their sources.
This editorial highlights that while evening administration of candesartan may reduce morning albuminuria more than morning dosing, methodological limitations such as open-label design and baseline imbalances necessitate cautious interpretation and further outcome-driven trials.
The increasing availability of out-of-office blood pressure (BP) monitoring techniques, in particular of ambulatory BP monitoring (ABPM) and of BP monitoring at home (HBPM) allows the physicians to get a more detailed information on the efficacy of antihypertensive drug coverage over different periods of the day in nonhospitalized patients [1,2]. Based on this information physicians may now identify the best timing of drug administration to attain BP control over subperiods of the day and night when it is not adequate. This ‘chronotherapeutic’ approach is theoretically justified by the data showing that inadequate control of BP may be particularly detrimental during night-time and morning hours [3–5] as well as by the available studies showing the superiority of out-of-office over office BP in predicting cardiovascular outcomes also in treated hypertensive patients [6,7]. Several studies have also shown that evening administration of drugs may actually be helpful in achieving nocturnal and morning BP control [8,9]. This apparently obvious finding is only reasonable if relatively short acting antihypertensives, such as ramipril [10] or doxazosine [11] are used. However, one should not necessarily expect important differences in the temporal distribution of antihypertensive efficacy between morning and evening drug administration, if drugs characterized by long and sustained action (i.e. with trough-to-peak ratio close to 100%) are used [12]. Even more importantly, a direct demonstration that evening administration may additionally reduce the risk of adverse sequelae of nocturnal or morning hypertension is still lacking. The above considerations clearly indicate that there is a large gap in the scientific evidence behind the popular and common sense-driven practice of modifying drug intake time to achieve improvement in BP control throughout the 24 h. In particular, it is still unclear whether evening drug administration carries clinical advantages as compared with morning drug dosing (Table 1).Table 1: Pros and cons of evening administration of antihypertensive drugsThe study by Kario et al.[13] published in the current issue of the Journal of Hypertension was designed to address some aspects of the above problem. In this study hypertensive patients were randomized to receive a relatively long acting angiotensin receptor blocker, candesartan, once a day either in the morning or in the evening. The titration strategy was based on home BP measurements and its target was to achieve adequate control of both morning and evening systolic home BP (<135 mmHg). Addition of a diuretic was allowed if BP control was not achieved with the maximum allowed dosage of candesartan in monotherapy (12 mg). With such a design, the authors aimed at achieving comparable morning and evening BP control in both groups. Avoidance of differences in BP control between morning and evening would allow this study to assess pressure-independent effects of morning vs. evening administration of candesartan on study outcomes, including albumin excretion rate (AER) and plasma B-type natriuretic peptide level. The main result of the study by Kario et al.[13] is the finding that in the evening administration group a more pronounced reduction in AER occurred as compared to the morning administration group, with no major differences between groups in terms of either morning or evening BP levels achieved by treatment. Although the contribution of this study is important, some caution is warranted in its interpretation, because of several limitations most of which were duly acknowledged by the authors in the discussion. First, the study had an open label design and therefore the biases commonly associated with this approach may not be completely excluded. Second, microalbuminuria was assessed in a morning urine sample rather than in total urine output of the 24 h. This is an important issue because, although albumin/creatinine ratio in morning urine sample is currently recommended by guidelines for risk stratification in hypertension [14], in the specific setting of the study by Kario et al.[13] an ‘acute’ direct effect of the evening dose of candesartan on albumin excretion may have been particularly pronounced in the morning, and this finding may not necessarily represent the effect of treatment on the global 24-h urinary albumin excretion. Moreover, caution is needed also in the interpretation of the prognostic relevance of these findings in relation to patients' cardiovascular morbid and fatal events. Needless to say, microalbuminuria is not a direct measure of cardiovascular risk and its more pronounced reduction over a period of several hours does not necessarily translate into prognostic benefit. Third, the randomization procedure seems to have failed in the case of between group distribution of the key study outcome. In fact there was a larger proportion of microalbuminuric patients at baseline in the evening administration group. These patients were thus likely to benefit more evidently from angiotensin II blockade, making the between-group difference in AER reduction (used by the authors as the main outcome measure) misleading when comparing the effects of morning and evening drug administration [13]. An interesting methodological peculiarity of the study by Kario et al. is the application of a BP measuring device for HBPM capable of providing a few automated measurements also at night-time, that is implementing a feature until now available only for 24 h ABPM. Unfortunately, this method was only used in a subgroup of patients, which, in combination with the small number of night-time measurements available (a maximum of three per patient) limited the power of night-time BP analysis. In fact, although night-time BP assessed with this approach appears lower in the morning administration than in the evening administration group, this difference was not statistically significant. This is in line with the somewhat lower values of evening BP also seen in the former group, which reached statistical significance at one point in the study. Obviously both these findings would require confirmation on a larger scale but, at least when administering long-acting drugs such as candesartan, they appear to challenge the common belief that evening administration of antihypertensive medications provides a better control of night-time BP. Moreover, the fact that nocturnal BP was similar (or even higher) in the evening administration group suggests that the observed differences in morning AER between groups did not depend on the effect of treatment on night-time BP. However, more robust data, as those provided by 24 h ABPM, would be needed to confirm this interpretation. Notwithstanding its limitations, the study provides stimulating evidence. One of its most interesting findings is that patients with isolated morning hypertension at baseline seem to derive greater benefit from the evening administration in terms of morning microalbuminuria reduction, despite similar achieved morning BP levels, compared with patients with evening hypertension at baseline. This might be particularly important in the light of previous evidence suggesting that morning home BP values may be more closely related with outcomes compared to the evening ones [15]. As a general comment, the results obtained in the study by Kario et al.[13] seem to support the suggestion that evening drug administration may be better than morning dosing, at least in some patients. However, with regard to the general applicability of the recommendation to administer antihypertensive drugs in the evening more than in the morning in a clinical setting, it is also important to remember that some studies have reported a lower therapeutic adherence by patients with such an approach [16]. This may not necessarily be the case in the controlled setting of a clinical study, but it may create difficulties in translating its results into real life application. Finally, it is worth mentioning that an important AER reduction was attained in patients who, because of the study inclusion criteria, had moderately elevated clinic BP and also high home BP. This is probably because patients with white-coat hypertension, much less likely to benefit from antihypertensive treatment, were excluded from the study. This indirectly underlines the important role of out-of-office BP in hypertension management, which allows more accurate risk stratification, and thus better-tailored therapeutic strategies by physicians [17]. Although the study by Kario et al. represents an important step towards a better understanding of the clinical relevance of antihypertensive medication timing, undoubtedly further studies are needed in this area, in particular focusing on ‘hard’ cardiovascular outcomes. Implementation of a correct methodology in such studies is of uttermost importance, to allow a proper interpretation of their results, as exemplified by the problem of morning vs. 24 h albuminuria assessment. Moreover, a careful interpretation of the variety of information provided by out-of-office BP monitoring techniques is warranted, because morning, evening, night-time and daytime BP values are linked with each other, and may all have a combined importance in determining the patient's outcome [18]. Acknowledgment The authors have no conflicts of interest to declare.
No takes yet. Share an insight, caveat, or question.
Parati et al. (2010) conducted an editorial in Hypertension. Evening administration of candesartan vs. Morning administration of candesartan was evaluated on Albumin excretion rate (AER). Evening administration of candesartan resulted in a more pronounced reduction in albumin excretion rate compared to morning administration, despite similar achieved blood pressure levels.
Synapse has enriched 10 related papers. Consider them for comparative context: